BACKGROUND: The cytokines that act as inflammatory hormones show a role in coronary atherosclerotic disease. AIMS: This study aimed to measure serum resistin, IL-6 levels and lipid profile in nondiabetic controls, diabetics, and ischemic heart disease subjects with and without diabetes. Association between resistin and IL-6 was also determined. MATERIALS & METHODS: In this comparative cross-sectional study, 147 subjects were selected, aged between 40 and 70 years. Subjects were divided into four groups as mentioned above. Plasma glucose was measured using the gluco-oxidase method. Lipid profile levels were measured using standard enzymatic methods. Levels of resistin and IL-6 were determined by ELISA. RESULTS: Out of 147 patients, 36 were controls and 111 were cases. Serum resistin and IL-6 levels increased significantly in diabetics (23.4 ± 0.74 ng/ml and 73.1 ± 2.57 ng/ml, respectively) and nondiabetics with ischemic heart disease (14.1 ± 0.51 ng/ml and 66.2 ± 2.08 ng/ml, respectively) compared with diabetics and nondiabetic controls. Positive correlations were found between IL-6 and resistin, and a significant positive correlation was shown in ischemic heart disease groups (r = 0.659; p = 0.001). CONCLUSION: This study shows that the plasma resistin and IL-6 concentrations increased significantly in patients with ischemic heart disease with and without diabetes. This shows that there is a possible role of resistin and IL-6 in inflammatory processes, especially in atherosclerosis.
BACKGROUND: The cytokines that act as inflammatory hormones show a role in coronary atherosclerotic disease. AIMS: This study aimed to measure serum resistin, IL-6 levels and lipid profile in nondiabetic controls, diabetics, and ischemic heart disease subjects with and without diabetes. Association between resistin and IL-6 was also determined. MATERIALS & METHODS: In this comparative cross-sectional study, 147 subjects were selected, aged between 40 and 70 years. Subjects were divided into four groups as mentioned above. Plasma glucose was measured using the gluco-oxidase method. Lipid profile levels were measured using standard enzymatic methods. Levels of resistin and IL-6 were determined by ELISA. RESULTS: Out of 147 patients, 36 were controls and 111 were cases. Serum resistin and IL-6 levels increased significantly in diabetics (23.4 ± 0.74 ng/ml and 73.1 ± 2.57 ng/ml, respectively) and nondiabetics with ischemic heart disease (14.1 ± 0.51 ng/ml and 66.2 ± 2.08 ng/ml, respectively) compared with diabetics and nondiabetic controls. Positive correlations were found between IL-6 and resistin, and a significant positive correlation was shown in ischemic heart disease groups (r = 0.659; p = 0.001). CONCLUSION: This study shows that the plasma resistin and IL-6 concentrations increased significantly in patients with ischemic heart disease with and without diabetes. This shows that there is a possible role of resistin and IL-6 in inflammatory processes, especially in atherosclerosis.